About this Research Topic
The therapeutic management of chronic respiratory disease (CRDs) with the majority of past and a few of the current conventional approaches is outdated and necessitates the development of newer, advanced therapeutic delivery systems. Novel therapeutic delivery systems have recently emerged with promising scopes across all diseases, including CRDs. Researchers are now interested in the application of nanoparticle-based formulation or genetic material (siRNA, miRNA, decoy oligonucleotide) targeted/loaded formulation in the management of airway inflammation or to slow down the progression of CRDs. In fact, some of these formulations have proven very effective in pre-clinical animal models and in vitro studies. Therefore, this field represents a fertile research area, which may further explore various therapeutic candidates, plants based single compounds, and transcription factors to study their efficacy in CRDs.
There is a lack of robust therapeutic delivery methods for management of CRDs such as COPD and lung cancer. With conventional methods of delivery, it is likely that the drug administered via various routes such as oral, possesses the risk low bioavailability, degradation in GI environment (for oral medicine) and need of high dose to achieve therapeutic efficacy with the increased risk of side effects. Advanced therapeutic delivery systems aim to tackle these problems with primary focus on improving the potency of drugs with less dose and fewer consequent side effects. Therefore, more research is necessary to validate application of various advanced drug delivery systems for CRDs.
In this Research Topic, we aim to welcome the submission of high quality original and review papers that includes study of advanced drug delivery for CRDs across the full range of delivery methods, route (lung/oral/IV/SubQ), vector/carrier and disease. Areas of interest include, but are not limited to:
• Targeting CRDs with liquid crystalline nanoparticles, solid-lipid nanoparticles etc.
• Targeting CRDs with siRNA, miRNA, transcription factor decoy oligodeoxynucleotides based advance therapeutic formulation.
• Advanced aerosol, nebulization and inhalation therapy for CRDs.
• Application of advanced therapeutic delivery for in vitro and in vivo CRDs models.
• Challenges in the pulmonary delivery of therapeutics.
Guest Editor Dr. Ronan MacLoughlin declares that they are Associate Director at R&D, Science and Emerging Technologies, Aerogen Ltd, Ireland. Aerogen designs and manufactures nebulisers for drug delivery to the lungs. All other Guest Editors declare no conflicts of interest.
There is a lack of robust therapeutic delivery methods for management of CRDs such as COPD and lung cancer. With conventional methods of delivery, it is likely that the drug administered via various routes such as oral, possesses the risk low bioavailability, degradation in GI environment (for oral medicine) and need of high dose to achieve therapeutic efficacy with the increased risk of side effects. Advanced therapeutic delivery systems aim to tackle these problems with primary focus on improving the potency of drugs with less dose and fewer consequent side effects. Therefore, more research is necessary to validate application of various advanced drug delivery systems for CRDs.
In this Research Topic, we aim to welcome the submission of high quality original and review papers that includes study of advanced drug delivery for CRDs across the full range of delivery methods, route (lung/oral/IV/SubQ), vector/carrier and disease. Areas of interest include, but are not limited to:
• Targeting CRDs with liquid crystalline nanoparticles, solid-lipid nanoparticles etc.
• Targeting CRDs with siRNA, miRNA, transcription factor decoy oligodeoxynucleotides based advance therapeutic formulation.
• Advanced aerosol, nebulization and inhalation therapy for CRDs.
• Application of advanced therapeutic delivery for in vitro and in vivo CRDs models.
• Challenges in the pulmonary delivery of therapeutics.
Guest Editor Dr. Ronan MacLoughlin declares that they are Associate Director at R&D, Science and Emerging Technologies, Aerogen Ltd, Ireland. Aerogen designs and manufactures nebulisers for drug delivery to the lungs. All other Guest Editors declare no conflicts of interest.
Keywords: Drug Delivery, Chronic Respiratory Disease, Nanoparticles, Pulmonary Medicine, Therapeutic Delivery
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
